SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert L. Ray who wrote (92)10/28/1998 5:58:00 PM
From: ADEL 7  Read Replies (1) of 127
 
Using Renalgel will cost approximately $1100/year for one dialysis patient. The cost of Ca CO3 is less than $ 150/year.
Renagel is a great drug and FDA will approve it for sure but its market potential is questionable . Because of the cost , Renagel will be used for a subset of patients who can not take calcium carbonate or Phos Lo ( calcium acetate)such as patients with hypercalcemia or aluminum toxicity ( very small number of patients). The market potential of 200-300 millions is very unrealistic in my estimation.
Good luck to all
Adel7
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News